Transaction expected to provide shareholders with immediate value.
Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company, has announced an agreement to be acquired by Gurnet Point Capital and Novo Holdings. As part of the deal, the purchasing organizations will assume all debt and responsibilities associated with the purchase. The upfront payment at closing represents a premium of 41% over the closing price of Paratek's common stock as of May 31, 2023, which was the last full trading day prior to market speculation regarding a potential sale of the company.
"This transaction will deliver immediate value to our shareholders at a substantial premium while allowing them to also benefit from the future value created by NUZYRA through the CVR," said Evan Loh, M.D., Chief Executive Officer at Paratek. "Today's announcement is a testament to all we've accomplished at Paratek over the past several years. Both our Board of Directors and our management team are proud of Paratek's accomplishments with NUZYRA and look forward to Gurnet Point and Novo Holdings continuing to deliver upon our goal of providing lifesaving, transformative therapies to patients."
Reference: Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings. Paratek Pharma. June 6, 2023. Accessed June 7, 2023. https://www.paratekpharma.com/investor-relations/press-release
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.